Trial · NCT04735861
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
NCT04735861, Phase 2, Completed, Tongji Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma. Trials, record NCT04735861. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04735861
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
- NCT number
- NCT04735861
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 38 participants, actual
- Lead sponsor
- Tongji Hospital
- Conditions
- Ovarian Clear Cell Carcinoma
- Interventions
- Sintilimab, Bevacizumab Biosimilar IBI305
- First posted
- 2021-02-03
- Last updated
- 2024-08-13
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | Up to 3 years | ORR is defined as the proportion of patients with complete response(CR) and partial response(PR) assessed by the investigator in accordance with the RECIST 1.1 criteria. |
| Secondary | Progression-free survival (PFS) | Up to 3 years | PFS is defined as the time from enrollment to the first imaging disease progression or death (whichever occurs first). Assessed according to RECIST v1.1 by investigator. |
| Secondary | Time to response (TTR) | Up to 2 years | TTR is defined as the time from the first administration to the first CR or PR recorded. Assessed according to RECIST v1.1 by investigator. |
| Secondary | Duration of remission (DOR) | Up to 3 years | DOR is defined as the time interval from the first record of disease response to disease progression or death (whichever occurs first). Assessed according to RECIST v1.1 by investigator. |
| Secondary | Disease control rate (DCR) | Up to 5 years | DCR is defined as the proportion of the patients with complete response, partial remission, and stable disease after treatment. Assessed according to RECIST v1.1 by investigator. |
| Secondary | Overall survival (OS) | Up to 5 years | OS is defined as the time between enrollment and the patient's death due to any cause. |
| Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Up to 3 years | Safety includes the adverse event profile of sintilimab and bevacizumab according to the Common Terminology Criteria for Adverse Events version 5.0. |
| Secondary | Quality of life assessment of patients | Quality of life will be assessed by Functional Assessment of Cancer Therapy-Ovarian (FACT-O) | Quality of life will be assessed by Functional Assessment of Cancer Therapy-Ovarian (FACT-O) and other scales as appropriate. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04735861
GET https://conductscience.org/api/trials/v1/NCT04735861/registered